The company today announced strong long-term follow-up data from the initial Episealer trial done in Sweden.
ANNONS
We previously saw 24-month data; the patients have now been followed for 75 months and the data still looks excellent. This is important for Episurf Medical, as many doctors as well as payers request long-term follow-up for the implant system to be included in treatment algorithms and reimbursement systems.
